NASDAQ:NYMX - Nymox Pharmaceutical Corporation
$2.09
 $0.09
+4.50%
4:00PM EDT
2019-04-18
Nymox Pharmaceutical Corp is a Canada-based biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company operates through the research and development of products for the aging population segment. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also owns rights for its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex, Inc. conducts research and development, and manufacturing of NicAlert and TobacAlert. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NYMX     avg for
industry  
  avg for
sector  
42 stocks weight:  0. 54   199. 07   233. 87  
42 stocks rank:  3. 82 K 1. 43 K 1. 06 K
# analyst opinions:  1. 00   14. 48   14. 09  

quick ratio:  7. 41   5. 29   1. 92  
current ratio:  7. 47   5. 64   2. 40  

target price low:  3. 26   84. 50   115. 74  
target price avg:  3. 26   110. 73   137. 39  
target price high:  3. 26   136. 41   157. 80  
1-yr high:  4. 30   114. 11   138. 85  
last close:  2. 09   87. 56   116. 78  
50-day avg:  2. 15   95. 43   123. 53  
200-day avg:  2. 28   94. 13   121. 20  
1-yr low:  1. 31   72. 67   98. 41  
volume:  118. 91 K 2. 43 M 4. 85 M
50-day avg volume:  92. 12 K 2. 72 M 4. 97 M
200-day avg volume:  107. 97 K 2. 90 M 4. 58 M

1-day return:  4. 50 % -0. 40 % 0. 07 %
this week return:  15. 47 % -5. 72 % -4. 11 %
12-wk return:  -3. 69 % 1. 78 % -0. 04 %
52-wk return:  -51. 34 % 10. 81 % 14. 09 %

enterprise value (EV):  127. 41 M 51. 19 B 117. 96 B
market cap:  141. 44 M 43. 00 B 104. 52 B
EBITDA:  -10. 64 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -11. 98   4. 34   13. 27  
enterprise/revenue (EV/R):  426. 11   68. 16   13. 68  
total revenue:  299. 00 K 10. 61 B 38. 24 B
total debt:  0. 00   12. 22 B 16. 66 B
net income (common):  -10. 59 M 2. 20 B 4. 21 B

shares outstanding:  67. 68 M 570. 91 M 1. 24 B
shares:  36. 37 M 571. 02 M 1. 23 B
shares short:  1. 52 M 9. 93 M 16. 79 M
shares short prior month:  1. 35 M 9. 96 M 16. 58 M
short ratio:  16. 19   5. 31   3. 30  
short % of float:  4. 90 % 5. 81 % 2. 61 %
total cash/share:  0. 12   11. 13   9. 30  
total cash:  7. 95 M 6. 70 B 7. 10 B
free cash flow:  -3. 91 M 3. 58 B 4. 74 B
operating cash flow:  -7. 80 M 4. 14 B 6. 32 B

book value:  0. 11   12. 76   26. 84  
price/book:  19. 35   3. 08   -1. 74  
operating margins:  -3558. 86 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  53. 85 % 37. 02 % 55. 68 %

1-yr max volatility:  19. 85 % --- ---
1-yr mean volatility:  -0. 20 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 17   2. 39   4. 08  
P/E:  -11. 94   13. 59   22. 83  
PE/G:  0. 15   -1. 46   1. 68  
growth:  -81. 90 % 126. 81 % 29. 29 %
earnings high:  -0. 00   1. 02   1. 63  
earnings avg:  -0. 00   0. 76   1. 51  
earnings low:  -0. 00   0. 47   1. 39  
revenue high:  -0. 00   2. 68 B 10. 71 B
revenue avg:  -0. 00   2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -146. 89 % -2. 80 % 5. 29 %
return on equity:  -368. 42 % -18. 52 % 7. 38 %
revenue growth:  -81. 90 % 92. 55 % 19. 15 %
revenue/share:  0. 01   13. 27   55. 24  

beta (1yr vs S&P500):  0. 85   1. 24   0. 93  
sharpe (1yr):  -0. 72   0. 29   0. 60  

held % insiders:  41. 49 % 6. 38 % 3. 38 %
held % institutions:  6. 37 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : NYMX
.    + 1.271 =         1.271 :: INITIAL WEIGHT
.   + 45.453 =        46.723 :: spline projection addition
.    x 1.432 =        66.909 :: industry recommendation factor
.    x 4.099 =       274.272 :: EV/R factor
.    x 0.985 =       270.243 :: return on assets factor
.    x 0.963 =       260.286 :: return on equity factor
.    x 0.992 =       258.155 :: revenue growth factor
.    x 2.675 =       690.471 :: current ratio factor
.    x 1.075 =       742.364 :: quick ratio factor
.     x 1.03 =       764.947 :: short ratio factor
.    x 2.351 =      1798.588 :: price-to-book factor
.    x 1.932 =      3474.374 :: P/E weight
.    x 1.618 =      5622.383 :: PE/G factor
.    x 1.672 =      9398.506 :: beta factor
.    x 0.716 =      6729.267 :: sharpe factor
.    x 1.809 =     12174.482 :: target low factor
.     x 1.25 =     15214.284 :: target mean factor
.    x 1.075 =     16353.923 :: target high factor
.    x 1.312 =     21450.597 :: industry 2-weeks return factor
.    x 0.876 =     18787.544 :: "drift" penalty 1 days ago
.    x 0.973 =     18285.583 :: "drift" penalty 3 days ago
.    x 0.971 =     17754.333 :: "drift" penalty 4 days ago
.    x 0.984 =     17472.894 :: "drift" penalty 5 days ago
.    x 0.977 =     17072.933 :: overall "drift" factor
.    x 0.802 =     13684.411 :: largest single-day jump factor
.    x 0.066 =       906.853 :: low price factor
.      x 1.0 =       906.707 :: factor hist industry gain for week 15
.   cubeRoot =         9.679 :: reduced to standardize
.   - 23.409 =         0.539 :: add/subtract for performance
.                      0.539 :: FINAL WEIGHT for NASDAQ:NYMX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org